Piramal Enterprises has been granted a patent for a pharmaceutical combination involving a CDK inhibitor and an antioxidant enzyme inhibitor for treating various cancers. The patent also includes a pharmaceutical kit with instructions for administering the combination therapy. GlobalData’s report on Piramal Enterprises gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Piramal Enterprises, Cancer treatment biomarkers was a key innovation area identified from patents. Piramal Enterprises's grant share as of April 2024 was 36%. Grant share is based on the ratio of number of grants to total number of patents.
Pharmaceutical kit for cancer treatment with cdk and antioxidant
A recently granted patent (Publication Number: US11925618B2) discloses a pharmaceutical kit designed for use in combination therapy with an antioxidant enzyme inhibitor for the treatment of various cancers including head and neck cancer, lung cancer, gastrointestinal cancer, blood and/or lymphatic system cancer, or breast cancer. The kit includes the cyclin-dependent kinase (CDK) inhibitor voruciclib, the antioxidant enzyme inhibitor, and a package insert containing instructions for administering the combination therapy to patients in need of treatment.
The patent further specifies that the antioxidant enzyme inhibitor in the kit can be selected from a range of inhibitors such as glutathione peroxidase inhibitor, glutathione reductase inhibitor, thioredoxin reductase (TrxR) inhibitor, and others. Additionally, the kit may include an additional CDK inhibitor along with voruciclib. The package insert provides comprehensive information on indications, usage, doses, administration directions, contraindications, precautions, and warnings. Moreover, the kit may contain a pharmaceutically acceptable buffer, water for injection, phosphate-buffered saline, Ringer's solution, or dextrose solution to facilitate administration. The composition of voruciclib in the kit is specified as (+)-2-(2-chloro-4-trifluoromethylphenyl)-5,7-dihydroxy-8-(2-hydroxymethyl-1-methylpyrrolidin-3-yl)-chromen-4-one, or its hydrochloride salt, highlighting the precise formulation for effective treatment.
To know more about GlobalData’s detailed insights on Piramal Enterprises, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
